Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million.
The Irving, Texas-based firm, backed by investment giants Sixth Street and Neuberger Berman, has already conducted 6.5 million molecular tests across 849,000 patient cases, establishing partnerships with over 100 biopharmaceutical firms, including Moderna Inc (NASDAQ:MRNA) and AbbVie (NYSE:ABBV), according to its prospectus filed with the U.S. Securities and Exchange Commission.
Don’t Miss:
Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — this is your last chance to become an investor for $0.80 per share.
Inspired by Uber and Airbnb – Deloitte’s fastest-growing software company is transforming 7 billion smartphones into income-generating assets – with $1,000 you can invest at just $0.30/share!
Valuation Context and Financial Performance
The $5.35 billion target—based on 23.5 million shares priced between $16 and $18 each—marks a notable shift from Caris’ 2021 private valuation of $7.83 billion, Reuters reported, reflecting both market recalibration and the challenges of commercializing precision medicine.
According to its filing, Caris generated $412.3 million in revenue in 2024—a 35% year-over-year increase—while posting a net loss of $257.1 million. In Q1 2025, the company reported $120.9 million in revenue and a narrowed net loss of $127 million, compared to $80.7 million in revenue and a $134.1 million loss during the same period in 2024, according to its filing—signaling improving margins and sustained top-line growth.
At its proposed valuation, Caris would trade at approximately 13 times sales, a premium to peers like Guardant Health (NASDAQ: GH) and Tempus AI (NASDAQ: TEM), Reuters reported.
Trending: Invest where it hurts — and help millions heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold.
Technology and Competitive Edge
According to the company’s website, Caris was founded in 2008 by entrepreneur David D. Halbert, who was inspired by his father’s cancer battle to develop more effective, data-driven diagnostics. Today, the company operates from its North Texas headquarters and has offices in Phoenix, New York, Cambridge, Massachusetts, Tokyo, Japan, and Basel, Switzerland, serving both U.S. and international markets.
Caris’ proprietary AI platform, which integrates molecular science with machine learning, analyzes comprehensive genomic, transcriptomic, and proteomic data to guide cancer treatment. The company holds 27 issued patents along with over 170 applications pending worldwide, according to its website. Its flagship MI Cancer Seek test, cleared by the U.S. Food and Drug Administration in 2023, detects early-stage malignancies with what the company claims is unmatched accuracy, the company said at the time.
Investor Sentiment and Sector Implications
Caris will trade on the Nasdaq under the symbol CAI The offering is led by BofA Securities, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets. Grand View Research projects a 22.5% CAGR in the AI cancer diagnostics market through 2030, highlighting strong growth potential in this sector.
See Also: Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation
Neuberger Berman has indicated it may purchase up to $75 million worth of shares in the IPO—signaling insider confidence in the company’s long-term potential, according to Reuters.
Regulatory and Market Risks
Caris Life Sciences currently has one FDA-cleared diagnostic test, MI Cancer Seek, according to its filing.
Caris’ pipeline includes investigational tools like FOLFIRSTai, an AI-based test for predicting chemotherapy response in metastatic colorectal cancer. While clinically validated, it remains unapproved by the FDA, according to the SEC filing, and stricter regulations could delay its commercialization.
Conclusion: A Litmus Test for AI Biotech
Caris’s proposed IPO is drawing attention as a potential marker for the viability of AI-driven healthcare, with Reuters noting the offering comes amid renewed interest in precision diagnostics.
Read Next:
Are you rich? Here’s what Americans think you need to be considered wealthy.
Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can invest with $1,000 at just $0.30/share.
Image: Shutterstock
“ACTIVE INVESTORS’ SECRET WEAPON” Supercharge Your Stock Market Game with the #1 “news & everything else” trading tool: Benzinga Pro – Click here to start Your 14-Day Trial Now!
Get the latest stock analysis from Benzinga?
MODERNA (MRNA): Free Stock Analysis Report
This article AI Meets Oncology: Caris Life Sciences’ $5.35B IPO Tests Investor Appetite for Precision Medicine originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
